Zevalin (ibritumomab) Disease Interactions
There are 3 disease interactions with Zevalin (ibritumomab):
Ibritumomab tiuxetan (applies to Zevalin) cytopenia
Major Potential Hazard, Moderate plausibility. Applicable conditions: Bone Marrow Depression/Low Blood Counts
The use of ibritumomab tiuxetan may result in severe and prolonged cytopenias. Do not administer the ibritumomab tiuxetan therapeutic regimen to patients with >= 25% lymphoma marrow involvement and/or impaired bone marrow reserve. It is recommended to monitor patients for signs of cytopenia for up to 3 months after treatment and for hematological toxicity including development of myelodysplastic syndrome and/or acute myelogenous leukemia.
Ibritumomab tiuxetan (applies to Zevalin) vaccination
Major Potential Hazard, Moderate plausibility.
The safety of immunization with live viral vaccines following the ibritumomab tiuxetan has not been studied. Do not administer live viral vaccines to patients who have recently received ibritumomab tiuxetan. The ability to generate an immune response to any vaccine following the therapeutic regimen has not been studied.
Ibritumomab tiuxetan (applies to Zevalin) hematological toxicity
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Myelodysplastic Disease, Leukemia
The radiation dose resulting from therapeutic exposure to Y-90 radiolabeled ibritumomab tiuxetan may result in secondary malignancies. Myelodysplastic syndrome (MDS) and/or acute myelogenous leukemia (AML) has been reported in clinical trials with ibritumomab tiuxetan. It is recommended to monitor patients for hematological toxicity including development of MDS or AML.
Zevalin (ibritumomab) drug interactions
There are 237 drug interactions with Zevalin (ibritumomab)
More about Zevalin (ibritumomab)
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- Drug class: CD20 monoclonal antibodies
Related treatment guides
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No interaction information available.|